Statins lower LDL cholesterol, the cholesterol carried by the particles that build plaque in artery walls. In large randomized trials, that drop in LDL led to fewer heart attacks, fewer strokes and fewer procedures to reopen blocked arteries.
The size of the benefit depends on two things: how far your LDL falls, and how high your risk was to begin with. This guide explains what the trials measured, how to read the numbers, and which groups guidelines have in mind. It is not a recommendation to take or avoid a statin.
Key takeaways
- Statins slow cholesterol production in the liver, and the liver responds by clearing more LDL from the blood.
- Pooled trial data show roughly a one-fifth drop in major vascular events for every 39 mg/dL of LDL lowering.
- The relative benefit is similar across risk levels, but the absolute benefit is larger when starting risk is higher.
- US guidelines tie statin decisions to estimated risk, LDL level, diabetes, kidney disease and existing heart disease.
- Any decision to begin, pause or adjust a statin belongs with the clinician who prescribes it.
How a statin lowers LDL
Your liver makes most of the cholesterol in your body. Statins partly block an enzyme the liver needs for that work. With less cholesterol made inside its own cells, the liver puts more LDL receptors on its surface and pulls more LDL particles out of the bloodstream.
How much LDL falls depends on the statin and its strength. The most potent statins lower LDL cholesterol by 55% to 60% on average at their highest strength.1 Lower-intensity treatment produces a smaller drop.
Fewer LDL particles in the blood means fewer particles entering the artery wall. Our guide to arterial plaque explains why that matters.
What the trials found
The best single source is the Cholesterol Treatment Trialists' Collaboration, a group that pools patient-level data from the large statin trials. Its 2010 analysis covered 26 trials and about 170,000 people.
Across those trials, each 1.0 mmol/L reduction in LDL cholesterol, about 39 mg/dL, lowered the yearly rate of major vascular events by just over a fifth.2 Major vascular events meant heart attack, death from coronary disease, stroke, or a procedure to restore blood flow to the heart.
Deaths from any cause fell by 10% for each 1.0 mmol/L of LDL lowering, mostly because fewer people died of heart disease. The same analysis found no significant effect on cancer rates or on deaths from non-vascular causes.
Trials that compared stronger statin treatment with weaker treatment pointed the same way: more LDL lowering, fewer events.
Relative benefit and absolute benefit are different numbers
"About a fifth fewer events" is a relative figure. What it means for one person depends on how likely an event was in the first place.
A second pooled analysis looked at this directly. In people whose five-year risk of a major vascular event was below 10%, each 1 mmol/L of LDL lowering prevented about 11 major vascular events per 1,000 people over five years.3 The relative reduction in these lower-risk groups was at least as large as in higher-risk groups.
Put simply:
- If your risk is high, a one-fifth reduction removes a large slice of risk.
- If your risk is low, the same one-fifth reduction removes a small slice.
- A bigger LDL drop gives a bigger reduction at any risk level.
This is why guidelines start with an estimate of your risk. Our PREVENT calculator guide explains how that estimate is made.
Who guidelines recommend statins for
Guidelines differ in detail, and they change. Two current US sources are summarized here.
| Source | Group | Position |
|---|---|---|
| US Preventive Services Task Force, 2022 | Adults 40 to 75 with no cardiovascular disease, at least one risk factor, and 10-year risk of 10% or more | Clinicians should prescribe a statin |
| US Preventive Services Task Force, 2022 | Same group, 10-year risk of 7.5% to under 10% | Selectively offer a statin; the likely benefit is smaller |
| US Preventive Services Task Force, 2022 | Adults 76 or older with no cardiovascular disease | Evidence is insufficient to judge starting a statin |
| 2026 ACC/AHA dyslipidemia guideline | LDL cholesterol of 190 mg/dL or higher, diabetes, or chronic kidney disease | Eligible for a statin without needing a risk calculation |
The Task Force names dyslipidemia, diabetes, high blood pressure and smoking as the risk factors that count.4 Its statement predates the PREVENT calculator, so its percentages and the 2026 guideline's risk bands should not be compared directly.
For everyone else without known heart disease, the 2026 guideline uses the PREVENT risk estimate to guide the decision.5 One analysis estimated that the 2026 guideline extends statin consideration to adults aged 30 to 59 whose 30-year risk is 10% or higher, even when their 10-year risk is under 3%.6 That change adds many younger, lower-risk adults, and the decision for them is a shared one.
For people who already have heart or artery disease, statins remain the first-line cholesterol treatment in both US and European guidance.
What statins do not do
- They do not remove risk. Risk that remains on treatment is covered in our guide for people already on a statin, along with how statins affect calcium scores and Lp(a).
- They are not free of side effects. See statin side effects for what blinded trials found.
- They do not replace the rest of prevention. Blood pressure, blood sugar, smoking, activity and food still count.
Do not begin, pause or adjust any medication without first talking with the clinician who prescribes it. That includes changes prompted by a lab result or by anything in this guide.
Next step: know the numbers behind the decision
A statin discussion goes better when you know your LDL, your ApoB, your Lp(a) and your estimated risk. Both Cardio Res-Q assessments, the Comprehensive Assessment ($775) and the Enhanced Assessment ($999), include ApoB, Lp(a) and hs-CRP along with a clinical evaluation. The Enhanced Assessment adds a calcium score and a CIMT ultrasound.
Details are on the Cardio Res-Q program page. The clinic prescribes statins and non-statin medicines case by case, and it can share your results with your own doctor.
Are You a Candidate for Cardio Res-Q?
Three quick questions about the risk factors we screen for. Your answers stay between you and the clinic.
Frequently asked questions
How much do statins lower the chance of a heart attack?
In pooled trial data, major vascular events fell by a little more than one-fifth for each 39 mg/dL (1.0 mmol/L) drop in LDL cholesterol. A larger LDL drop was linked to a larger reduction. How many events that prevents for you depends on your starting risk, so ask your clinician to put it in absolute terms.
Do statins help people who have never had a heart problem?
Yes, on average. A pooled analysis found that the relative benefit in people at lower risk was at least as large as in people at higher risk. The absolute benefit is smaller because fewer events were going to happen anyway, which is why guidelines match the decision to estimated risk.
Do statins lower Lp(a)?
No. Statins act on LDL, and pooled data show Lp(a) rises slightly on statin treatment. Lp(a) is inherited, and no approved drug lowers it. A high Lp(a) is usually a reason for doctors to manage other risk factors more firmly.
Related reading
This article is for general education and is not medical advice. Decisions about testing and medication should be made with your clinician. If you have chest pain or other symptoms of a heart attack, call 911.
